Skip to content

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial

64
Academic
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Abstract Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and ...
The DECISION trial provides some evidence that low-dose digoxin may have benefits for patients with heart failure in terms of improving functional class, symptoms, and reducing hospitalizations. However, the trial did not find a significant difference between the digoxin group and the placebo group in terms of the primary outcome measure, which was a composite of cardiovascular death, hospitalization for worsening heart failure, and unplanned visits to the emergency department due to heart failu...